<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7474329\results\search\disease\results.xml">
  <result pre="in a credit line to the data. Abstract Incidents of" exact="viral" post="outbreaks have increased at an alarming rate over the"/>
  <result pre="to 2.68. However, the ratio between mortality and number of" exact="infections" post="seems to be lower in this case in comparison"/>
  <result pre="ratio between mortality and number of infections seems to be" exact="lower" post="in this case in comparison to other human coronaviruses"/>
  <result pre="case in comparison to other human coronaviruses (such as severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
  <result pre="in comparison to other human coronaviruses (such as severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
  <result pre="comparison to other human coronaviruses (such as severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV))."/>
  <result pre="as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV)). These outbreaks have tested the limits"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV)). These outbreaks have tested the limits of"/>
  <result pre="terms of prevention, diagnosis and treatment of COVID-19 and other" exact="viral" post="infections. In this review, we discuss the use of"/>
  <result pre="followed by approximately 13 downstream ORFs. The rest of the" exact="viral" post="genome encodes essential structural proteins that are spike (S),"/>
  <result pre="COVID-19 available yet. The current treatments are mainly based on" exact="symptomatic" post="relief and respiratory support in seriously ill patients [15,"/>
  <result pre="The current treatments are mainly based on symptomatic relief and" exact="respiratory" post="support in seriously ill patients [15, 16]. Efforts to"/>
  <result pre="conserved key proteins [17, 18], such as those involved in" exact="viral" post="replication and proliferation. Examples of these proteins are spike,"/>
  <result pre="envelope proteins, as well as RNA proteases, which are specific" exact="viral" post="targets. Host receptors and proteases, which are responsible for"/>
  <result pre="Most of the currently available drugs for the treatment of" exact="viral" post="infections fall in one of the followings classes: antiviral"/>
  <result pre="of the currently available drugs for the treatment of viral" exact="infections" post="fall in one of the followings classes: antiviral therapies,"/>
  <result pre="on natural products [22]. The effectiveness of conventional treatments of" exact="viral" post="infections progressively fades away because of viral mutations and"/>
  <result pre="natural products [22]. The effectiveness of conventional treatments of viral" exact="infections" post="progressively fades away because of viral mutations and the"/>
  <result pre="conventional treatments of viral infections progressively fades away because of" exact="viral" post="mutations and the resulting emergence of new viral strains"/>
  <result pre="because of viral mutations and the resulting emergence of new" exact="viral" post="strains [23]. Recently, the development of broad-spectrum antiviral drugs"/>
  <result pre="development of alternative antiviral therapies, targeting different phases in the" exact="viral" post="replication cycle [26, 27]. In this regard, nanotechnology has"/>
  <result pre="been investigated for potential use in prevention and/or treatment of" exact="viral" post="infections [28â€&quot;30]. Nanotechnology can be broadly defined as design"/>
  <result pre="investigated for potential use in prevention and/or treatment of viral" exact="infections" post="[28â€&quot;30]. Nanotechnology can be broadly defined as design and"/>
  <result pre="the fight against COVID-19 through different approaches, such as avoiding" exact="viral" post="contamination and spray by: (a) design of infection-safe personal"/>
  <result pre="highly specific and sensitive nano-based sensors to quickly identify the" exact="infection" post="or immunological response; (c) development of new drugs, with"/>
  <result pre="of antiviral drugs [28, 29]. In addition, due to the" exact="absence of" post="therapeutic choices for various viral infections, many attempts have"/>
  <result pre="addition, due to the absence of therapeutic choices for various" exact="viral" post="infections, many attempts have been done to explore the"/>
  <result pre="Moreover, nano-based biosensors could be used in diagnostics for the" exact="viral infection" post="with high specificity and sensitivity [39, 40]. Another very"/>
  <result pre="nano-based biosensors could be used in diagnostics for the viral" exact="infection" post="with high specificity and sensitivity [39, 40]. Another very"/>
  <result pre="cells [43â€&quot;45] (Fig.Â 1). Fig.Â 1 Schematic representation of SARS-CoV-2" exact="infection" post="and the nanotechnologies tools to prevent and control COVID-19."/>
  <result pre="and schools, are a well-recognized common source for outbreaks of" exact="infection" post="[46, 47]. Some studies have shown the potential of"/>
  <result pre="shown the potential of nano-based surface coatings for prevention of" exact="infections" post="[48â€&quot;50]. Also, the protection of healthcare workers is very"/>
  <result pre="the protection of healthcare workers is very important in a" exact="viral" post="outbreak. This is where nano-based antimicrobial technologies can be"/>
  <result pre="COVID-19. The emphasis is on how nanotechnology can help fight" exact="viral" post="infections and take account of any challenges in this"/>
  <result pre="The emphasis is on how nanotechnology can help fight viral" exact="infections" post="and take account of any challenges in this regard."/>
  <result pre="resistant to constant washing and friction, in addition to presenting" exact="non-toxic" post="properties. Nanomaterials for surface decontamination This is where nanotechnology"/>
  <result pre="active ingredient (hydrogen peroxide) doses needed for inactivation were significantly" exact="lower" post="(nanogram level), indicating the viability of this platform. The"/>
  <result pre="self-cleaning system for surfaces based on crystal nanoparticles, with one" exact="non-toxic" post="system that did not generate residues. The nanoparticles promote"/>
  <result pre="as well as obtaining self-disinfecting surfaces to improve efficacy for" exact="infection" post="control and health and environmental safety. TableÂ 1 shows"/>
  <result pre="authors, treatment with CAC-717 allowed caused a reduction in the" exact="viral" post="load to below the detection limit after 2Â min"/>
  <result pre="antiviral mechanism of the systems was the interaction with the" exact="viral" post="components located on the membrane [71] Nanoparticles Titanium dioxide"/>
  <result pre="According to the authors, there was a significant reduction in" exact="viral" post="load under light and dark conditions, with an increase"/>
  <result pre="as carrier agents in order to mitigate the transmission of" exact="infectious diseases" post="from surfaces. According to the inventors, the cartridges are"/>
  <result pre="surfaces. According to the inventors, the cartridges are water-soluble and" exact="non-toxic" post="and can be composed of different sanitizing agents, also"/>
  <result pre="a viricidal formulation and its use in the treatment of" exact="viral" post="infections, as well as for sterilization and disinfection. The"/>
  <result pre="a high viricidal activity of the system, also showing a" exact="residual" post="effect [79] Biogenic nanoparticles Silver The invention describes obtaining"/>
  <result pre="method that uses natural reducing agents presents a moderate reaction," exact="short" post="synthesis time and low production cost [80] Photocatalytic systems"/>
  <result pre="nanoparticles doped with palladium nanoparticles (concentration of 0.1â€&quot;5% of the" exact="total" post="weight of tungsten trioxide nanoparticles). The authors describe the"/>
  <result pre="of nanomaterials for PPE According the United States Centers for" exact="Disease" post="Control and Prevention (CDC), the main factors for the"/>
  <result pre="for the spread of COVID-19 is close contact (person-to-person) and" exact="respiratory" post="droplets produced by infected persons [86]. The use of"/>
  <result pre="facemasks not fitting properly or not suitable for restricting airborne" exact="viral" post="particles [87, 88]. Nanotechnology is offering new materials that"/>
  <result pre="99.999% of airborne particles with potential to be applied as" exact="respiratory" post="protection [101] Metal oxide nanoparticles (silver and copper) Face"/>
  <result pre="must also be evaluated for any side effects, such as" exact="skin irritation," post="allergy, or toxic effects, in humans. On the other"/>
  <result pre="negative environmental impacts. Strategies using nanotechnology for virus detection and" exact="disease" post="diagnosis Viruses are simple biological structures, size in the"/>
  <result pre="observed by ordinary optical microscopes [105, 106]. As with other" exact="viral" post="infections, SARS-CoV-2 requires rapid response tests [64], with operational"/>
  <result pre="implementation of control measures for the isolation and tracking of" exact="infections" post="[108]. Specifically, when dealing with the detection and diagnosis"/>
  <result pre="the body and are based on the presence of specific" exact="viral" post="antigens or corresponding antibody responses of the immune system."/>
  <result pre="important limitation occurs in the diagnosis of individuals with a" exact="viral" post="load in its initial representation or when a mutation"/>
  <result pre="platform can be easily adapted for the diagnosis of other" exact="infectious diseases," post="such as COVID-19. Other tests incorporating gold nanoparticles combined"/>
  <result pre="with antibodies against SARS-CoV-2 IgG/IgM showed the potential for rapid" exact="symptomatic" post="and asymptomatic screening for COVID-19 [114]. Transcription of the"/>
  <result pre="of sensors [104]. It is known that, among the SARS-related" exact="viral" post="genomes, three regions have conserved sequences, which are the"/>
  <result pre="detection with considerable analytical sensitivity [109, 115]. The extraction of" exact="viral" post="RNA is also the focus of the nanotechnology application,"/>
  <result pre="with the appropriate receptors, nanoparticles can act by specifically recruiting" exact="viral" post="proteins during the formation of corona proteins [120]. Therefore,"/>
  <result pre="100% (96/96) Oropharynx swab 60Â min for the whole diagnosis" exact="Absence of" post="cross reactions Colorimetric [122] Lanthanide-doped polysterene nanoparticles SARS-CoV-2 Was"/>
  <result pre="negative Results of this assay: 8 positive and 11 negative" exact="Blood" post="serum 10Â min â€&quot; Fluorimetric [123] Poly (amino ester)"/>
  <result pre="carboxyl groups coated magnetic nanoparticles (pcMNP) SARS-CoV-2 LOD: 10 copies" exact="Linear" post="range: 10â€&quot;105 copies Pseudovirus samples diluted in foetal calf"/>
  <result pre="min â€&quot; Colorimetric [114] Gold nanoislands SARS-CoV-2 LOD: 0.22Â pmol/L" exact="Linear" post="range: 0.1Â pmol/Lâ€&quot;1Â Î¼mol/L Recovery rate: 26/5000 96% in"/>
  <result pre="Zinc ferrite nanoparticles SARS-CoV-2 â€&quot; â€&quot; 15Â min Extract the" exact="viral" post="RNA through automation processâ€‰+â€‰subsequent RT-PCR reactions â€&quot; Direct RT-PCR"/>
  <result pre="Direct RT-PCR [125] Nanopore target sequencing (NTS) SARS-CoV-2 and other" exact="respiratory" post="viruses simultaneously LOD: 10 copies Linear range: 10â€&quot;3000 copies"/>
  <result pre="(NTS) SARS-CoV-2 and other respiratory viruses simultaneously LOD: 10 copies" exact="Linear" post="range: 10â€&quot;3000 copies Specificity: 100% (5/5) Oropharyngeal swabs 6â€&quot;10Â"/>
  <result pre="qPCR [126] Spike (S) protein specific nanoplasmonic resonance sensor SARS-CoV-2" exact="Linear" post="range: 103 virus particle/mLâ€&quot;106 virus particle/mL LOD: 750 vp/mL"/>
  <result pre="[127] Carriers and drug delivery systems with potential to control" exact="viral infection" post="With the pandemic caused by SARS-CoV-2, it is necessary"/>
  <result pre="Carriers and drug delivery systems with potential to control viral" exact="infection" post="With the pandemic caused by SARS-CoV-2, it is necessary"/>
  <result pre="potential mechanism of action, an aim to change or inactivate" exact="viral" post="surface proteins, such as the spike glycoprotein, thatÂ is"/>
  <result pre="into cells [130, 131] or act in the inhibition of" exact="viral" post="replication [132]. Although investigations regarding the efficacy of these"/>
  <result pre="prone to loss of effectiveness as a result of possible" exact="viral" post="mutations and development of resistance [67â€&quot;69]. There is some"/>
  <result pre="approved by the FDA for the treatment of emerging viruses." exact="Viral" post="epidemics are challenging from a therapeutic and public health"/>
  <result pre="are 90 antiviral active drugs approved for the treatment of" exact="viral" post="infections. Nevertheless, the administration of these drugs is often"/>
  <result pre="as hepatotoxicity and nephrotoxicity [136], while ribavirin is associated to" exact="haemolytic anaemia" post="[137]. Most side effects of antiviral drugs are generated"/>
  <result pre="hepatotoxicity and nephrotoxicity [136], while ribavirin is associated to haemolytic" exact="anaemia" post="[137]. Most side effects of antiviral drugs are generated"/>
  <result pre="decrease the side effects and toxicity of conventional treatments of" exact="viral" post="infections. In addition, it will be possible to decrease"/>
  <result pre="avoids its accumulation in inflammatory sites. In this way, the" exact="uncontrolled" post="recruitment of monocytes in inflammatory processes was solved, with"/>
  <result pre="and alpha-tocopherol (vitamin E), for targeted action in regions of" exact="acute" post="inflammation [147]. Mice in an acute hyperinflammatory state and"/>
  <result pre="action in regions of acute inflammation [147]. Mice in an" exact="acute" post="hyperinflammatory state and with cytokine storm were treated with"/>
  <result pre="an increase in the levels of IL-10 were observed, mitigating" exact="uncontrolled" post="inflammation. In addition, it was observed that the encapsulation"/>
  <result pre="site, this nano-based formulation holds promise as a treatment for" exact="uncontrolled" post="inflammation caused by coronavirus. Also, curcumin has shown antiviral"/>
  <result pre="by coronavirus. Also, curcumin has shown antiviral activity against several" exact="viral" post="infections, including hepatitis, influenza, Zika virus, chikungunya virus and"/>
  <result pre="activity against several viral infections, including hepatitis, influenza, Zika virus," exact="chikungunya" post="virus and other sexually transmitted viruses. Just recently, Loutfy"/>
  <result pre="recently, Loutfy et al. synthesized chitosan nanoparticles loading curcumin against" exact="hepatitis C" post="virus genotype 4a. Chitosan nanoparticles were able to inhibit"/>
  <result pre="genotype 4a. Chitosan nanoparticles were able to inhibit 100% of" exact="viral infection" post="and replication in human hepatoblastoma cells (Huh7) [148]. The"/>
  <result pre="4a. Chitosan nanoparticles were able to inhibit 100% of viral" exact="infection" post="and replication in human hepatoblastoma cells (Huh7) [148]. The"/>
  <result pre="to inhibit 100% of viral infection and replication in human" exact="hepatoblastoma" post="cells (Huh7) [148]. The antiviral activity of nanoparticles containing"/>
  <result pre="Nanoparticles were able to inhibit both virus entry into the" exact="hepatoblastoma" post="cell and replication. Curcumin is just one example within"/>
  <result pre="of natural compounds that can potentially be used to control" exact="viral" post="infections, including COVID-19. Therefore, the use of nano-based formulations"/>
  <result pre="formulations has indicated a great potential for the control of" exact="viral" post="infections, where nanoparticles can both enhance the efficacy of"/>
  <result pre="as nanogels, which can capture the viable virus particles or" exact="viral" post="RNA/proteins, are also promising developments that can help in"/>
  <result pre="of nano-based formulations that can successfully target precise sites of" exact="viral infection" post="(e.g. the respiratory system in the case of COVID-19),"/>
  <result pre="nano-based formulations that can successfully target precise sites of viral" exact="infection" post="(e.g. the respiratory system in the case of COVID-19),"/>
  <result pre="can successfully target precise sites of viral infection (e.g. the" exact="respiratory" post="system in the case of COVID-19), reduce drug toxicity"/>
  <result pre="improve the bioavailability and interaction of the latter with the" exact="viral" post="particles. The activity of some nanomaterials (e.g. silver and"/>
  <result pre="the compounds in several ways (e.g. facilitate interaction with the" exact="viral" post="particles, interfere with their entry into cells, increase bioavailability"/>
  <result pre="cell [151]. According to the authors, the CQDs inhibit the" exact="infection" post="either by interaction with the S protein of HCoV-229E"/>
  <result pre="of approach could be useful for the inhibition of an" exact="infection" post="with SARS-CoV-2 at different stages of the infection. Fig.Â"/>
  <result pre="inhibition of protein S receptor interaction, and b inhibition of" exact="viral" post="RNA genome replication (Reprinted with permission from Loczechin et"/>
  <result pre="mercaptoethanesulfonate (Au-MES NPs) to mimic this receptor, aiming to inhibit" exact="herpes" post="simplex virus type 1 (HSV-1) attachment to cells [154]."/>
  <result pre="to mimic this receptor, aiming to inhibit herpes simplex virus" exact="type 1" post="(HSV-1) attachment to cells [154]. This strategy interferes with"/>
  <result pre="to another. Although this study was carried out with the" exact="herpes" post="virus, this tool can also be explored for the"/>
  <result pre="virus associates with these structures and undergoes deformation, losing its" exact="infectious" post="potential. The nanoparticles caused the definitive inhibition of different"/>
  <result pre="the definitive inhibition of different viruses, such as HSV, human" exact="papilloma" post="virus (HPV), respiratory syncytial virus (RSV), dengue and lentivirus"/>
  <result pre="of different viruses, such as HSV, human papilloma virus (HPV)," exact="respiratory" post="syncytial virus (RSV), dengue and lentivirus in vitro, HSV-2"/>
  <result pre="the control of SARS-CoV-1 using siRNA [159]. Gene expression and" exact="viral" post="replication were inhibited in Vero E6 cells employing siRNAs,"/>
  <result pre="coding sequence for 3-chymotrypsin-like protease (nsp5) and the RNA polymerase-dependent" exact="viral" post="RNA as targets for siRNA. However, due to its"/>
  <result pre="tissues [163]. Nanoparticles as carrier systems for clustered regularly interspaced" exact="short" post="palindromic repeats (CRISPR) CRISPR is a gene editing technique"/>
  <result pre="with guide RNA were used to inhibit and degrade the" exact="viral" post="genome and synthesize mRNA in a targeted manner. Promising"/>
  <result pre="triggering the hostâ€™s immune system needs to be developed [167]." exact="Viral" post="vectors (e.g. AAV) are the most common type of"/>
  <result pre="of DNA mutation in vitro and in mice afflicted by" exact="Duchenne muscular dystrophy" post="[170]. Many recent studies have focused on the development"/>
  <result pre="DNA mutation in vitro and in mice afflicted by Duchenne" exact="muscular dystrophy" post="[170]. Many recent studies have focused on the development"/>
  <result pre="generations of vaccine formulations used to elicit immunological responses against" exact="infectious diseases," post="including attenuated or inactivated whole pathogen (first generation), recombinant"/>
  <result pre="and animals. However, the genetic reversion of attenuated vaccines or" exact="infection" post="of immunocompromised hosts, as well as the likely tumorgenicity"/>
  <result pre="working on a cocktail vaccine aiming to generate at least" exact="partial" post="protection against SARS-CoV-2 while waiting for more efficient vaccines"/>
  <result pre="for COVID-19 were developed right after the publication of the" exact="complete" post="genome of SARS-CoV-2. According to a report produced by"/>
  <result pre="conventional approaches. TableÂ 4 Nano-based vaccine candidates to prevent COVID-19" exact="infection" post="Name Developer Method/platform Development phase Moderna coronavirus vaccine National"/>
  <result pre="COVID-19 vaccine candidate BIOCAD (Russia) LNPs formulated with recombinant vesicular" exact="stomatitis" post="virus (rVSV) that expresses mRNA from SARS-CoV-2 Pre-clinical COVID-19"/>
  <result pre="already been employed in the diagnosis and treatment of other" exact="viral" post="diseases and may provide a â€œfresh startâ€� for trying"/>
  <result pre="simplify the multidrug therapies that are currently used to treat" exact="infectious diseases" post="[106]. Nanotechnology applications, however, have some bottlenecks that need"/>
  <result pre="been shown to enhance diagnostics, protection and therapies in other" exact="viral" post="infections; therefore, there is a good chance that, with"/>
  <result pre="declare that they have no competing interests. References References 1.DhamaKPawaiyaRVSChakrabortSTiwariRSaminathanMVermaAKCoronavirus" exact="infection" post="in equines: a reviewAsian J Anim Vet Adv20149164176 2.SchoemanDFieldingBCCoronavirus"/>
  <result pre="Vet Adv20149164176 2.SchoemanDFieldingBCCoronavirus envelope protein: current knowledgeVirol J2019166931133031 3.ZhouPYangX-LWangX-GHuBZhangLZhangWet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet.202039550751332007143 6.LiuYGayleAAWilder-SmithARocklÃ¶vJThe reproductive number"/>
  <result pre="and receptor bindingLancet.202039556557432007145 10.WuFZhaoSYuBChenY-MWangWSongZ-Get al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526932015508 11.WanYShangJGrahamRBaricRSLiFReceptor recognition by the novel coronavirus"/>
  <result pre="receptor bindingLancet.202039556557432007145 10.WuFZhaoSYuBChenY-MWangWSongZ-Get al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526932015508 11.WanYShangJGrahamRBaricRSLiFReceptor recognition by the novel coronavirus from"/>
  <result pre="the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected" exact="pneumonia" post="(standard version)Military Med Res.202074 16.ZumlaAHuiDSAzharEIMemishZAMaeurerMReducing mortality from 2019-nCoV: host-directed"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microb Infect20209221236 18.VellingiriBJayaramayyaKIyerMNarayanasamyAGovindasamyVGiridharanBet al.COVID-19: a promising"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microb Infect20209221236 18.VellingiriBJayaramayyaKIyerMNarayanasamyAGovindasamyVGiridharanBet al.COVID-19: a promising"/>
  <result pre="Infect20209221236 18.VellingiriBJayaramayyaKIyerMNarayanasamyAGovindasamyVGiridharanBet al.COVID-19: a promising cure for the global panicSci" exact="Total" post="Environ202072513827732278175 19.HuiLYemingWJiuyangXBinCPotential antiviral therapeutics for 2019 Novel CoronavirusChin J"/>
  <result pre="Respir Dis202043170172 20.ZhangJZhouLYangYPengWWangWChenXTherapeutic and triage strategies for 2019 novel coronavirus" exact="disease" post="in fever clinicsLancet Respir Med20208e11e1232061335 21.XiaBKangXActivation and maturation of"/>
  <result pre="progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human" exact="respiratory" post="disease: detection, mechanisms and treatmentInt J Antimicrob Agents.20205510595032234465 23.StrasfeldLChouSAntiviral"/>
  <result pre="mechanisms and clinical implicationsInfect Dis Clin N Am201024413437 24.JackmanJALeeJChoN-JNanomedicine for" exact="infectious disease" post="applications: innovation towards broad-spectrum treatment of viral infectionsSmall2016121133113926551316 25.ChenW-HStrychUHotezPJBottazziMEThe"/>
  <result pre="and clinical implicationsInfect Dis Clin N Am201024413437 24.JackmanJALeeJChoN-JNanomedicine for infectious" exact="disease" post="applications: innovation towards broad-spectrum treatment of viral infectionsSmall2016121133113926551316 25.ChenW-HStrychUHotezPJBottazziMEThe"/>
  <result pre="24.JackmanJALeeJChoN-JNanomedicine for infectious disease applications: innovation towards broad-spectrum treatment of" exact="viral" post="infectionsSmall2016121133113926551316 25.ChenW-HStrychUHotezPJBottazziMEThe SARS-CoV-2 vaccine pipeline: an overviewCurr Trop Med"/>
  <result pre="approaches and clinical perspectives of anthocyanins in the management of" exact="viral" post="diseasesFront Pharmacol.201910120731787892 28.LemboDDonalisioMCivraAArgenzianoMCavalliRNanomedicine formulations for the delivery of antiviral"/>
  <result pre="of antiviral drugs: a promising solution for the treatment of" exact="viral" post="infectionsExpert Opin Drug Deliv2018159311428749739 29.SinghLKrugerHGMaguireGEMGovenderTParboosingRThe role of nanotechnology in"/>
  <result pre="Drug Deliv2018159311428749739 29.SinghLKrugerHGMaguireGEMGovenderTParboosingRThe role of nanotechnology in the treatment of" exact="viral" post="infectionsTher Adv Infect Dis.2017410513128748089 30.SzuneritsSBarrasAKhanalMPagneuxQBoukherroubRNanostructures for the inhibition of"/>
  <result pre="viral infectionsTher Adv Infect Dis.2017410513128748089 30.SzuneritsSBarrasAKhanalMPagneuxQBoukherroubRNanostructures for the inhibition of" exact="viral" post="infectionsMolecules201520140511408126247927 31.ChoiYHHanH-KNanomedicines: current status and future perspectives in aspect"/>
  <result pre="al.Nanoscale virus biosensors: state of the artNDD.201544766 41.Al-HalifaSGauthierLArpinDBourgaultSArchambaultDNanoparticle-based vaccines against" exact="respiratory" post="virusesFront Immunol.2019102230733717 42.VijayanVMohapatraAUthamanSParkIKRecent advances in nanovaccines using biomimetic immunomodulatory"/>
  <result pre="phosphoproteomic analysis reveals differentially regulated proteins and pathway in PRRSV-Infected" exact="Pulmonary" post="Alveolar MacrophagesJ Proteome Res2014131270128024533505 44.PanHZhangPGaoDZhangYLiPLiuLet al.Noninvasive visualization of respiratory"/>
  <result pre="analysis reveals differentially regulated proteins and pathway in PRRSV-Infected Pulmonary" exact="Alveolar" post="MacrophagesJ Proteome Res2014131270128024533505 44.PanHZhangPGaoDZhangYLiPLiuLet al.Noninvasive visualization of respiratory viral"/>
  <result pre="PRRSV-Infected Pulmonary Alveolar MacrophagesJ Proteome Res2014131270128024533505 44.PanHZhangPGaoDZhangYLiPLiuLet al.Noninvasive visualization of" exact="respiratory" post="viral infection using bioorthogonal conjugated near-infrared-emitting quantum dotsACS Nano201485468547724797178"/>
  <result pre="Pulmonary Alveolar MacrophagesJ Proteome Res2014131270128024533505 44.PanHZhangPGaoDZhangYLiPLiuLet al.Noninvasive visualization of respiratory" exact="viral infection" post="using bioorthogonal conjugated near-infrared-emitting quantum dotsACS Nano201485468547724797178 45.ZhangYKeXZhengZZhangCZhangZZhangFet al.Encapsulating"/>
  <result pre="Alveolar MacrophagesJ Proteome Res2014131270128024533505 44.PanHZhangPGaoDZhangYLiPLiuLet al.Noninvasive visualization of respiratory viral" exact="infection" post="using bioorthogonal conjugated near-infrared-emitting quantum dotsACS Nano201485468547724797178 45.ZhangYKeXZhengZZhangCZhangZZhangFet al.Encapsulating"/>
  <result pre="surfaces. In: Use of biocidal surfaces for reduction of healthcare" exact="acquired" post="infections. Springer International Publishing AG; 2014. p. 7â€&quot;26. 47.GellerCVarbanovMDuvalREHuman"/>
  <result pre="new antiseptic strategiesViruses.201243044306823202515 48.LeeW-SHsiehT-CShiauJCOuT-YChenF-LLiuY-Het al.Bio-Kil, a nano-based disinfectant, reduces environmental" exact="bacterial" post="burden and multidrug-resistant organisms in intensive care unitsJ Microbiol"/>
  <result pre="Immunol Infect20175073774627262208 49.KarunanayakeLIWaniganayakeYCGunawardenaKDNPadmarajaSADPeterDJayasekeraRet al.Use of silicon nanoparticle surface coating in" exact="infection" post="control: experience in a tropical healthcare settingInfect Dis Health.20192420120731324594"/>
  <result pre="Dis Health.20192420120731324594 50.OrtÃ­-LucasRMMuÃ±oz-MiguelJEffectiveness of surface coatings containing silver ions in" exact="bacterial" post="decontamination in a recovery unitAntimicrob Resist Infect Control.201766128630685 51.SiYZhangZWuWFuQHuangKNitinNet"/>
  <result pre="call for physical scientists and engineersACS Nano.20201443747375432267678 58.QueridoMMAguiarLNevesPPereiraCCTeixeiraJPSelf-disinfecting surfaces and" exact="infection" post="controlColloids Surf B Biointerfaces.201917882130822681 59.GeyerFDâ€™AcunziMSharifi-AghiliASaalAGaoNKaltbeitzelAet al.When and how self-cleaning"/>
  <result pre="against virus infectionCrit Rev Microbiol201642465624754250 63.VazeNPyrgiotakisGMcDevittJMenaLMeloABedugnisAet al.Inactivation of common hospital" exact="acquired" post="pathogens on surfaces and in air utilizing engineered water"/>
  <result pre="based codelivery of oseltamivir to inhibit the activity of the" exact="H1N1 Influenza" post="Virus through ROS-mediated signaling pathwaysACS Appl Mater Interfaces20168243852439327588566 69.KimJYeomMLeeTKimH-ONaWKangAet"/>
  <result pre="19 Apr 2020. 84.RÃ¶sch A, Schaefer C. Metal Dispersion with" exact="Increased" post="Stability. EP3368204A1. 2018. https://worldwide.espacenet.com/patent/search/family/057130386/publication/EP3368204A1?q=EP3368204A1&amp;amp;queryLang=en%3Ade%3Afr. 85.Liu Y, Sun W. Preparation"/>
  <result pre="silver/quaternary ammonium salt composite sanitizer. CN108391673A, 2018. https://worldwide.espacenet.com/patent/search/family/063091462/publication/CN108391673A?q=CN108391673A&amp;amp;queryLang=en%3Ade%3Afr. 86.CDC. Coronavirus" exact="disease" post="2019 (COVID-19)â€&quot;transmission. Centers for Disease Control and Prevention. 2020."/>
  <result pre="CN108391673A, 2018. https://worldwide.espacenet.com/patent/search/family/063091462/publication/CN108391673A?q=CN108391673A&amp;amp;queryLang=en%3Ade%3Afr. 86.CDC. Coronavirus disease 2019 (COVID-19)â€&quot;transmission. Centers for" exact="Disease" post="Control and Prevention. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html. Accessed 11"/>
  <result pre="and related methods. 2014. https://patents.google.com/patent/US20140041905A1/en. Accessed 27 Apr 2020. 95.ElstonDMOccupational" exact="skin disease" post="among health care workers during the coronavirus (COVID-19) epidemicJ"/>
  <result pre="related methods. 2014. https://patents.google.com/patent/US20140041905A1/en. Accessed 27 Apr 2020. 95.ElstonDMOccupational skin" exact="disease" post="among health care workers during the coronavirus (COVID-19) epidemicJ"/>
  <result pre="2019. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019160261. Accessed 23 June 2020. 104.UdugamaBKadhiresanPKozlowskiHNMalekjahaniAOsborneMLiVYCet al.Diagnosing COVID-19: the" exact="disease" post="and tools for detectionACS Nano2020143822383532223179 105.DrazMSShafieeHApplications of gold nanoparticles"/>
  <result pre="antiviral therapeutic agentsMater Sci Eng C2020112110924 107.ChengXChenGRodriguezWRMicro- and nanotechnology for" exact="viral" post="detectionAnal Bioanal Chem200939348750119052733 108.WarisAAliMKhanAUAliABasetAExploring pathophysiology of COVID-19 infection: faux"/>
  <result pre="targeted antisense oligonucleotide capped plasmonic nanoparticlesACS Nano2020147617762732437124 110.HalfpennyKCWrightDWNanoparticle detection of" exact="respiratory" post="infection: nanoparticle detection of respiratory infectionWIREs Nanomed Nanobiotechnol.20102277290 111.TalebianSWallaceGGSchroederAStellacciFCondeJNanotechnology-based"/>
  <result pre="nanoparticlesACS Nano2020147617762732437124 110.HalfpennyKCWrightDWNanoparticle detection of respiratory infection: nanoparticle detection of" exact="respiratory" post="infectionWIREs Nanomed Nanobiotechnol.20102277290 111.TalebianSWallaceGGSchroederAStellacciFCondeJNanotechnology-based disinfectants and sensors for SARS-CoV-2Nat"/>
  <result pre="immunosensor for the corona virus associated with the Middle East" exact="respiratory" post="syndrome using an array of gold nanoparticle-modified carbon electrodesMicrochim"/>
  <result pre="for the corona virus associated with the Middle East respiratory" exact="syndrome" post="using an array of gold nanoparticle-modified carbon electrodesMicrochim Acta2019186224"/>
  <result pre="application of a rapid IgM-IgG combined antibody test for SARS-CoV-2" exact="infection" post="diagnosisJ Med Virol.202010.1002/jmv.2572732869863 115.CormanVMLandtOKaiserMMolenkampRMeijerAChuDKet al.Detection of 2019 novel coronavirus"/>
  <result pre="coronavirus (2019-nCoV) by real-time RT-PCREuro Surveill2020252000045 116.ZhaoZCuiHSongWRuXZhouWYuXA simple magnetic nanoparticles-based" exact="viral" post="RNA extraction method for efficient detection of SARS-CoV-2Mol Biol202010.1101/2020.02.22.961268"/>
  <result pre="immunoassayAnal Chem2020927226723132323974 124.QiuGGaiZTaoYSchmittJKullak-UblickGAWangJDual-functional plasmonic photothermal biosensors for highly accurate severe" exact="acute" post="respiratory syndrome coronavirus 2 detectionACS Nano2020145268527732281785 125.SomvanshiSBKharatPBSarafTSSomwanshiSBShejulSBJadhavKMMultifunctional nano-magnetic particles"/>
  <result pre="Chem2020927226723132323974 124.QiuGGaiZTaoYSchmittJKullak-UblickGAWangJDual-functional plasmonic photothermal biosensors for highly accurate severe acute" exact="respiratory" post="syndrome coronavirus 2 detectionACS Nano2020145268527732281785 125.SomvanshiSBKharatPBSarafTSSomwanshiSBShejulSBJadhavKMMultifunctional nano-magnetic particles assisted"/>
  <result pre="124.QiuGGaiZTaoYSchmittJKullak-UblickGAWangJDual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory" exact="syndrome" post="coronavirus 2 detectionACS Nano2020145268527732281785 125.SomvanshiSBKharatPBSarafTSSomwanshiSBShejulSBJadhavKMMultifunctional nano-magnetic particles assisted viral"/>
  <result pre="respiratory syndrome coronavirus 2 detectionACS Nano2020145268527732281785 125.SomvanshiSBKharatPBSarafTSSomwanshiSBShejulSBJadhavKMMultifunctional nano-magnetic particles assisted" exact="viral" post="RNA-extraction protocol for potential detection of COVID-19Mater Res Innov.20202416"/>
  <result pre="for the accurate and comprehensive detection of SARS-CoV-2 and other" exact="respiratory" post="virusesSmall.202016322002169 127.HuangLDingLZhouJChenSChenFZhaoCet al.One-step rapid quantification of SARS-CoV-2 virus particles"/>
  <result pre="generic microplate reader and point-of-care deviceBioRxiv.2020142373118 128.SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a reviewJAMA2020323181824183632282022 129.SalviRPatankarPEmerging pharmacotherapies for COVID-19Biomed Pharmacother202012811026732410772"/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirusJ Biol Chem20202954773477932094225 133.AndersenPIIanevskiALysvandHVitkauskieneAOksenychVBjÃ¸rÃ¥sMet al.Discovery and development of"/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirusJ Biol Chem20202954773477932094225 133.AndersenPIIanevskiALysvandHVitkauskieneAOksenychVBjÃ¸rÃ¥sMet al.Discovery and development of safe-in-man"/>
  <result pre="directions of uses, mechanisms of actions and toxic manifestations from" exact="malaria" post="to multifarious diseasesJ Antimicrob Chemother2015701608162125693996 137.ThomasEGhanyMGLiangTJThe application and mechanism"/>
  <result pre="application and mechanism of action of ribavirin in therapy of" exact="hepatitis" post="CAntivir Chem Chemother.20122311222592135 138.SofiasAMAndreassenTHakSNanoparticle ligand-decoration procedures affect in vivo"/>
  <result pre="diabetic retinopathyIJN.2019146357636931496691 145.GaoHXiongYZhangSYangZCaoSJiangXRGD and interleukin-13 peptide functionalized nanoparticles for enhanced" exact="glioblastoma" post="cells and neovasculature dual targeting delivery and elevated tumor"/>
  <result pre="enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated" exact="tumor" post="penetrationMol Pharm2014111042105224521297 146.DuncanSADixitSSahuRMartinDBaganiziDRNyairoEet al.Prolonged release and functionality of interleukin-10"/>
  <result pre="PLA-PEG nanoparticlesNanomaterials.201991074 147.DormontFBrusiniRCailleauCReynaudFPeramoAGendronAet al.Squalene-based multidrug nanoparticles for improved mitigation of" exact="uncontrolled" post="inflammation in rodentsSci Adv20206eaaz546632548259 148.LoutfySAElberryMHFarrohKYMohamedHTMohamedAAMohamedEBet al.Antiviral activity of chitosan"/>
  <result pre="Adv20206eaaz546632548259 148.LoutfySAElberryMHFarrohKYMohamedHTMohamedAAMohamedEBet al.Antiviral activity of chitosan nanoparticles encapsulating curcumin against" exact="hepatitis C" post="virus genotype 4a in human hepatoma cell linesIJN.2020152699271532368050 149.DeyPBergmannTCuellar-CamachoJLEhrmannSChowdhuryMSZhangMet"/>
  <result pre="sulfate in a length- and sequence-dependent mannerBioRxiv202010.1101/2020.05.10.08728832869034 156.CagnoVAndreozziPDâ€™AlicarnassoMJacob SilvaPMuellerMGallouxMet al.Broad-spectrum" exact="non-toxic" post="antiviral nanoparticles with a virucidal inhibition mechanismNat Mater.20181719520329251725 157.JonesSTCagnoVJaneÄ�ekMOrtizDGasilovaNPiretJet"/>
  <result pre="MERS-COV: a comparative overviewInfez Med.20202817418432275259 161.CeccarelliMBerrettaMVenanzi RulloENunnariGCacopardoBDifferences and similarities between" exact="Severe" post="Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a"/>
  <result pre="a comparative overviewInfez Med.20202817418432275259 161.CeccarelliMBerrettaMVenanzi RulloENunnariGCacopardoBDifferences and similarities between Severe" exact="Acute" post="Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose"/>
  <result pre="comparative overviewInfez Med.20202817418432275259 161.CeccarelliMBerrettaMVenanzi RulloENunnariGCacopardoBDifferences and similarities between Severe Acute" exact="Respiratory" post="Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by"/>
  <result pre="overviewInfez Med.20202817418432275259 161.CeccarelliMBerrettaMVenanzi RulloENunnariGCacopardoBDifferences and similarities between Severe Acute Respiratory" exact="Syndrome" post="(SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another"/>
  <result pre="interference as a prospective tool for the control of human" exact="viral" post="infectionsFront Microbiol.20189215130254624 164.RohiwalSSDvorakovaNKlimaJVaskovicovaMSeniglFSloufMet al.Polyethylenimine based magnetic nanoparticles mediated non-viral"/>
  <result pre="and prospectNano Res.20191224372450 168.AghamiriSTalaeiSGhavidelAAZandsalimiFMasoumiSHafshejaniNHet al.Nanoparticles-mediated CRISPR/Cas9 delivery: recent advances in" exact="cancer" post="treatmentJ Drug Deliv Sci Technol202056101533 169.GlassZLiYXuQNanoparticles for CRISPRâ€&quot;Cas9 deliveryNat"/>
  <result pre="adjuvants: formulating future vaccinesJ Clin Investig201612679926928033 174.SauttoGAKirchenbaumGADiottiRACriscuoloEFerraraFNext generation vaccines for" exact="infectious" post="diseasesJ Immunol Res.20192019589096231183388 175.LungPYangJLiQNanoparticle formulated vaccines: opportunities and challengesNanoscale.2020125746576332124894"/>
  <result pre="challengesNanoscale.2020125746576332124894 176.KimS-HJangY-SThe development of mucosal vaccines for both mucosal and" exact="systemic" post="immune induction and the roles played by adjuvantsClin Exp"/>
  <result pre="nanomaterial path forwardNat Nanotechnol20201564665532669664 181.EspesethASCejasPJCitronMPWangDDiStefanoDJCallahanCet al.Modified mRNA/lipid nanoparticle-based vaccines expressing" exact="respiratory" post="syncytial virus F protein variants are immunogenic and protective"/>
  <result pre="Vaccines.202051632128257 182.MoonJJSuhHPolhemusMEOckenhouseCFYadavaAIrvineDJAntigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a" exact="Plasmodium vivax malaria" post="vaccinePLoS ONE.20127e3147222328935 183.PapadopoulosNGMegremisSKitsioulisNAVangelatouOWestPXepapadakiPPromising approaches for the treatment and prevention"/>
  <result pre="lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax" exact="malaria" post="vaccinePLoS ONE.20127e3147222328935 183.PapadopoulosNGMegremisSKitsioulisNAVangelatouOWestPXepapadakiPPromising approaches for the treatment and prevention"/>
  <result pre="vaccinePLoS ONE.20127e3147222328935 183.PapadopoulosNGMegremisSKitsioulisNAVangelatouOWestPXepapadakiPPromising approaches for the treatment and prevention of" exact="viral" post="respiratory illnessesJ Allergy Clin Immunol201714092193228739285 184.GomesACMohsenMBachmannMFHarnessing nanoparticles for immunomodulation"/>
  <result pre="ONE.20127e3147222328935 183.PapadopoulosNGMegremisSKitsioulisNAVangelatouOWestPXepapadakiPPromising approaches for the treatment and prevention of viral" exact="respiratory" post="illnessesJ Allergy Clin Immunol201714092193228739285 184.GomesACMohsenMBachmannMFHarnessing nanoparticles for immunomodulation and"/>
  <result pre="VriesRDRimmelzwaanGFet al.Matrix-Mâ&quot;¢ adjuvant enhances immunogenicity of both protein- and modified" exact="vaccinia" post="virus Ankara-based influenza vaccines in miceImmunol Res20186622423329594879 193.Novavax. Novavax"/>
  <result pre="http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine. Accessed 16 June 2020. 194.ZhangCMaruggiGShanHLiJAdvances in mRNA vaccines for" exact="infectious" post="diseasesFront Immunol.20191059430972078 195.PardiNHoganMJPorterFWWeissmanDmRNA vaccinesâ€&quot;a new era in vaccinologyNat Rev"/>
  <result pre="200.MitchellSLCarlsonEETiny things with enormous impact: nanotechnology in the fight against" exact="infectious" post="diseaseACS Infect Dis.201841432143530070819 201.PolyakBCordovezBHow can we predict behavior of"/>
 </snippets>
</snippetsTree>
